Abstract OBJECTIVE: To study the expression of stromal cell derived factor-1(SDF-1) and CXC chemokine receptor 4 (CXCR4) in the airway and the effect of budesonide on their expression in mice with asthma. METHODS: Thirty BALB/c male mices were randomly divided into three groups: placebo control, untreated asthma, and budesonide-treated asthma. The asthma group were induced by intraperitoneal injection of 10% ovalbumin (OVA ) on days 1, 8 and 15, and then from days 22 to 34, challenged by inhalation of 2% OVA aerosol every other day. The budesonide-treated asthma group received an inhalation of budesonide (1 mg ) before OVA challenge. The pathological changes of the airway were assessed by hematoxylin and eosin staining. The immunohistochemistry was used to estimate the expression of SDF-1 in the lung. RT-PCR was used to evaluate the expression of CXCR4 in the lung. RESULTS: Compared with the control group, SDF-1 and CXCR4 expression in the lung in the untreated asthma group increased significantly (P<0.05). The budesonide-treated asthma group demonstrated significantly decreased SDF-1 (0.426±0.052 vs 0.361±0.065; P<0.05) and CXCR4 (0.829±0.027 vs 0.723±0.094; P<0.05) expression in the lung as compared with the untreated asthma group. Both SDF-1 (r=0.744, P<0.01) and CXCR4 (r=0.553, P<0.01）were positively correlated with the thickness of the airway wall. CONCLUSIONS: SDF-1 and CXCR4 may be associated with airway remodeling in mice with asthma. Budesonide can improve airway remodeling, possibly by decreasing the expression of SDF-1 and CXCR4.［Chin J Contemp Pediatr, 2010, 12 (3):215-218］
LUAN Bin,HUANG Xian-Jie,QIAO Jun-Ying. Expression of stromal cell derived factor-1 and CXC chemokine receptor 4 and the effects of budesonide on their expression in mice with asthma[J]. 中国当代儿科杂志, 2010, 12(3): 215-218.
LUAN Bin,HUANG Xian-Jie,QIAO Jun-Ying. Expression of stromal cell derived factor-1 and CXC chemokine receptor 4 and the effects of budesonide on their expression in mice with asthma[J]. CJCP, 2010, 12(3): 215-218.
［1］Du Q, Chen Z, Zhou LF, Zhang Q, Huang M, Yin KS. Inhibitory effects of astragaloside Ⅳ on ovalbumin-induced chronic experimental asthma［J］. Can J Physiol. Pharmacol, 2008, 86（7）: 449-457.
［2］Rydell-Tormanen K, Uller L, Erjefalt JS. Remodeling of extra-bronchial lung vasculature following allergic airway inflammation［J］. Respir Res, 2008, 9:18.
［3］Locke NR, Royce SG, Wainewright JS, Samuel CS, Tang ML. Comparison of airway remodeling in acute, subacute, and chronic models of allergic airways disease［J］.Am J Respir Cell Mol Biol, 2007, 36（5）:625-632.
［4］James AL, Wenzel S. Clinical relevance of airway remodeling in airway diseases［J］. Eur Respir J, 2007, 30（1）: 134-155.
［6］Gonzalo JA, Lloyd CM, Peled A, Delaney T, Coyle AJ, GutierrezRamos JC. Critical involvement of the chemotactic axis CXCR4/stromal cell-derived factor-1αin the Inflammatory component of allergic airway disease［J］. J Immunol, 2000, 165(1):499-508.
［7］Hoshino M, Aoike N, Takahashi M, Nakamura Y, Nakagawa T. Increased immunoreactivity of stromal cell-derived factor-1 and angiogenesis in asthma［J］. J Eur Respir, 2003, 21（5）:804-809.
［8］Salcedo R, Wasserman K, Young HA, Grimm MC, Howard OM, Anver MR, et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells［J］. Am J Pathol, 1999, 154（4）:1125-1135.
［9］McDonald DM. Angiogenesis and remodeling of airway vasculature in chronic inflammation［J］. Am J Respir Crit Care Med, 2001,164（10 Pt 2）: S39-S45.
［10］Eddleston J, Christiansen SC, Iuraw BL. Functional expression of the C-X-C chemokine receptor CXCR4 by human bronchial epithelial cells: regulation by proinfla-mmatory mediators［J］. J Immunol, 2002, 169(11): 6445-6451.
［11］Nagase H, Miyamasu M, Yamaguchi M, Fujisawa T, Ohta K, Yamamoto K, et al. Expression of CXCR4 in eosinophils: functional analyses and cytokine-mediated regulation［J］. J Immunol, 2000, 164(11): 5935-5943.
［12］Jourdan P, Abbal C, Nora N, Hori T, Uchiyama T, Vendrell JP, et al. Cutting ege: IL-4 induces functional cell-surface expression of CXCR4 on human T cells［J］. J Immunol, 1998, 160:4153-4157.
［13］Lukacs NW, Berlin A, Schols D, Skerlj RT, Bridger GJ. AMD3100, a CXCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity［J］. Am J Patbol, 2002, 160(4):1353-1360.
